期刊文献+

大麻素受体1在慢性乙型肝炎患者肝组织中的表达及其与炎症的关系

Relationship between inflammation and expression of cannabinoid receptor 1 in liver tissue of patients with chronic hepatitis B
下载PDF
导出
摘要 目的探讨大麻素受体1(CB1)在慢性乙型肝炎(CHB)患者肝组织中的定位表达及其与肝组织炎症损伤之间的关系。方法选择118例CHB患者进行肝组织活检,通过免疫组织化学染色检测肝组织中CB1表达情况。结果随着炎症分级(G)的不断加重,CB1评分也逐渐增加(P<0.05或<0.01)。在肝纤维化分期(S)相同的肝组织中,除S1外,S2、S3、S4患者的G评分与CB1评分呈显著相关性(rs分别为0.617、0.855、0.765,均P<0.01)。CB1评分与G评分呈显著相关性(rs=0.705,P<0.01);与血清ALT之间有一定相关性(rs=0.257,P<0.05),与血清HBV DNA之间无相关性(rs=-0.038,P>0.05)。结论内源性CB1在肝组织炎症损伤的演变过程中发挥了重要作用。 Objective To observe the expression and location of cannabinoid receptor 1(CB1) in liver tissue of patients with chronic hepatitis B(CHB),and to explore the relationship between expression of CB1 and inflammation in liver tissue.Methods Liver biopsy was performed in 118 patients with CHB.The expressions of CB1 in liver tissue were observed by immune histochemical technique.Results As the grade of hepatic inflammation became more severe,the expression of CB1 gradually became more intensive(P0.05 or 0.01).Moreover,in liver tissues with same liver fibrosis phase,the expression score of CB1 in CHB with S2,S3,S4 stages had significant relationship with the score of inflammation(rs=0.617,0.855,0.765,all P0.01).The expression score of CB1 had significant relationship with serum ALT(rs=0.257,P0.05),and had no relationship with serum HBV DNA(rs=-0.038,P0.05).Conclusion Endogenous CB1 plays an important role in the development of hepatic inflammation injury.
出处 《临床荟萃》 CAS 2010年第21期1864-1867,共4页 Clinical Focus
基金 中国肝炎防治基金会王宝恩肝纤维化研究基金项目(20080013) 河北省二○○八年医学科学研究重点课题计划(08190)
关键词 肝炎 乙型 慢性 受体 大麻酚 CB1 活组织检查 针吸 炎症 免疫组织化学 hepatitis B chronic cannabinoid receptor CB1 biopsy needle inflammation immunohisochemistry
  • 相关文献

参考文献9

  • 1Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fihrosls in chronic hepatitis C[J]. Hepatology, 2005,42 (1) : 63-71.
  • 2Teixeira-Clerc F, Julien B, Orenard P, et al. CB1 eannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis[J]. Nat Med,2006,12(6):671-676.
  • 3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 4高啸,郭燕,刘红艳,唐望先.血吸虫性肝纤维化小鼠肝组织中内源性大麻素1受体的表达[J].中华肝脏病杂志,2007,15(5):389-390. 被引量:13
  • 5Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids[J]. Pharmacol Ther, 2007,114 (1):13-33.
  • 6Caraceni P, Domenicali M, Giannone F, et al. The role of the endocannabinoid system in liver diseases [J ]. Baillieres Best Pract Res Clin Endocrinol Metab, 2009,23 ( 1 ) : 65-77.
  • 7Jaeschke H. Mechanisms of liver injury. Ⅱ. Mechanisms of neutrophil induced liver cell injury during hepatic ischemiareperfusion and other acute inflammatory conditions[J]. Am J Physiol Gastrointest Liver Physiol,2006,290(6) :G1083-1088.
  • 8Di Marzo V. Targeting the endocannabinoid system:to enhance or reduce? [J].Nat Rev Drug Discov,2008,7(5)=438-455.
  • 9Batkai S,Osei-Hyiaman D,Pan H,et al. Cannabinoid 2 receptor mediates protection against hepatic ischemia/reperfusion injury [J]. FASEB J,2007,21(8) :1788-1880.

二级参考文献21

共引文献1939

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部